CN116406288A8 - 使用PD-1拮抗剂、HIF-2α抑制剂、以及乐伐替尼或其药学上可接受的盐的组合，用于治疗癌症或冯-希佩尔-林道病的方法 - Google Patents

使用PD-1拮抗剂、HIF-2α抑制剂、以及乐伐替尼或其药学上可接受的盐的组合，用于治疗癌症或冯-希佩尔-林道病的方法 Download PDF

Info

Publication number
CN116406288A8
CN116406288A8 CN202180051960.9A CN202180051960A CN116406288A8 CN 116406288 A8 CN116406288 A8 CN 116406288A8 CN 202180051960 A CN202180051960 A CN 202180051960A CN 116406288 A8 CN116406288 A8 CN 116406288A8
Authority
CN
China
Prior art keywords
lenvatinib
hippel
hif
antagonist
von
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180051960.9A
Other languages
English (en)
Other versions
CN116406288A (zh
Inventor
R·F·佩里尼
E·M·皮涅罗
J·威尔曼罗杰里奥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Co Ltd
Merck Sharp and Dohme BV
Original Assignee
Eisai Co Ltd
Merck Sharp and Dohme BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd, Merck Sharp and Dohme BV filed Critical Eisai Co Ltd
Publication of CN116406288A publication Critical patent/CN116406288A/zh
Publication of CN116406288A8 publication Critical patent/CN116406288A8/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本文提供的是治疗癌症(例如，RCC)或冯-希佩尔-林道病的方法，其包括向有此需要的人患者施用：(a)PD-1拮抗剂；(b)HIF-2α抑制剂；以及(c)乐伐替尼或其药学上可接受的盐。还提供的是含有此类药剂的试剂盒和此类药剂的治疗组合用于治疗癌症的用途。
CN202180051960.9A 2020-06-17 2021-06-21 使用PD-1拮抗剂、HIF-2α抑制剂、以及乐伐替尼或其药学上可接受的盐的组合，用于治疗癌症或冯-希佩尔-林道病的方法 Pending CN116406288A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202063040225P 2020-06-17 2020-06-17
US63/040225 2020-06-22
US63/042225 2020-06-22
US202163146926P 2021-02-08 2021-02-08
US63/146926 2021-02-08
PCT/US2021/038171 WO2021262562A2 (en) 2020-06-17 2021-06-21 Methods for treating cancer or von-hippel lindau disease using a combination of a pd-1 antagonist, a hif-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereof

Publications (2)

Publication Number Publication Date
CN116406288A CN116406288A (zh) 2023-07-07
CN116406288A8 true CN116406288A8 (zh) 2024-02-13

Family

ID=80322273

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180051960.9A Pending CN116406288A (zh) 2020-06-17 2021-06-21 使用PD-1拮抗剂、HIF-2α抑制剂、以及乐伐替尼或其药学上可接受的盐的组合，用于治疗癌症或冯-希佩尔-林道病的方法

Country Status (4)

Country Link
EP (1) EP4168016A2 (zh)
CN (1) CN116406288A (zh)
AU (1) AU2021297151A1 (zh)
WO (1) WO2021262562A2 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115463217B (zh) * 2021-06-11 2024-03-12 深圳埃格林医药有限公司 己酸羟孕酮在增强肿瘤治疗效果中的应用
WO2023235236A1 (en) * 2022-06-02 2023-12-07 Merck Sharp & Dohme Llc Methods for treating cancer, or von-hippel lindau disease using a combination of a tigit antagonist, a pd-1 antagonist, and a hif-2-alpha inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017179739A1 (en) * 2016-04-15 2017-10-19 Eisai R&D Management Co., Ltd. Treatment of renal cell carcinoma with lenvatinib and everolimus
CA3020749A1 (en) * 2016-04-15 2017-10-19 Exelixis, Inc. Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
US10098860B2 (en) * 2016-07-20 2018-10-16 Cipla Limited Bezafibrate for the treatment of cancer
WO2018031680A1 (en) * 2016-08-10 2018-02-15 Fronthera U.S. Pharmaceuticals Llc Novel compounds, uses and methods for their preparation

Also Published As

Publication number Publication date
AU2021297151A1 (en) 2023-02-09
CN116406288A (zh) 2023-07-07
EP4168016A2 (en) 2023-04-26
WO2021262562A2 (en) 2021-12-30
WO2021262562A3 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
Gupta et al. Viral and nonviral uses of imiquimod: a review
Chiong et al. Randomized controlled study of mechanical percussion, diuresis, and inversion therapy to assist passage of lower pole renal calculi after shock wave lithotripsy
CN116406288A8 (zh) 使用PD-1拮抗剂、HIF-2α抑制剂、以及乐伐替尼或其药学上可接受的盐的组合，用于治疗癌症或冯-希佩尔-林道病的方法
AR048324A1 (es) Metodos para tratar infecciones por vih
AR048439A1 (es) Composiciones farmaceuticas y metodos para tratar la infeccion por vih
TW200505924A (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
MXPA05004778A (es) Metodos de uso y composiciones que contienen compuestos inmunomoduladores para el tratamiento y manejo de enfermedades mieloproliferativas.
DE602006017728D1 (de) Krebsbehandlung mittels fts und 2-deoxyglucose
CY1107203T1 (el) Χρηση αναστολεων της il - 18 για τη θεραπεια και/ή την προληψη καρδιακης νοσου
BRPI0413974A (pt) combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
NO20024646D0 (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
ATE396986T1 (de) Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
Bali et al. Cyclosporine reduces sclerosis in morphea: a retrospective study in 12 patients and a literature review
MX2022008216A (es) Tratamiento de cancer en combinacion usando un antagonista de pd-1, un antagonista de ilt4 y lenvatinib o sales del mismo.
JP2003528919A5 (zh)
MX2022016410A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un antagonista del pd-1, inhibidor de hif-2 alpha y lenvatinib o una sal aceptable farmeuticamente de estos.
BR112022012081A2 (pt) Método para tratar câncer, kit, e, uso de uma combinação terapêutica
MX2022016406A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib.
CL2023000296A1 (es) Uso de dexpramipexol para el tratamiento del asma moderado a grave
RU2005131578A (ru) Аплидин для лечения множественной миеломы
HUP0401188A2 (hu) Hiperelágazásos amilopektin sebészeti, gyógyító vagy diagnosztikai eljárásokban emlősöknél való alkalmazásra, különösen plazmatérfogat-növelőként
WO2022271810A3 (en) Bicyclic peptidyl pan-ras inhibitors
Scalvenzi et al. Efficacy and safety of vismodegib in patients with basal cell carcinoma: An Italian Center experience.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CI02 Correction of invention patent application
CI02 Correction of invention patent application

Correction item: Priority

Correct: 63/042225 2020.06.22 US|63/146926 2021.02.08 US

False: 63/040225 2020.06.22 US|63/146926 2021.02.08 US

Number: 27-02

Page: The title page

Volume: 39

Correction item: Priority

Correct: 63/042225 2020.06.22 US|63/146926 2021.02.08 US

False: 63/040225 2020.06.22 US|63/146926 2021.02.08 US

Number: 27-02

Volume: 39